Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility

MARINA DEL REY, Calif.: MARINA DEL REY, Calif., Nov. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company has entered into a new lease...

Click to view original post